Safety Study of Gintuit™ in Subjects Requiring Socket Grafting

NCT01929954 | Terminated Phase 1

• 1 other identifier: 11-PER-005-GT
• Study Type: interventional
• Target: 5
• Locations: 1 country
• Sites: 1

Brief Summary

This is a prospective, randomized, controlled, parallel group Phase 1/2 assessment of the safety of GINTUIT versus Bio-Gide in subjects who have a posterior tooth requiring extraction. The incidence and severity of adverse events will be summarized by group (GINTUIT and Bio-Gide).

Conditions

Edentulous Alveolar Ridge

Outcome Measures

Primary Outcomes (1)

• Number of participants with adverse events

  up to 12 months post treatment

Secondary Outcomes (15)

• Optimal product configuration (ie, single, folded, or z-folded)

  One month after placement of Gintuit in the last subject in the last successful cohort

• Number of participants reporting loose graft material

  Up to 21 days post treatment

• Percentage of participants with soft tissue closure

  Up to 4 weeks post treatment

• Measurements of bone height

  Up to 6 months post treatment

• Gintuit product handling

  At Day 0

Study Arms (2)

Gintuit

EXPERIMENTAL

Subjects with a posterior tooth (molar or premolar) socket created by atraumatic extraction will be grafted with freeze-dried bone allograft (ie, MinerOss™). The primary wound bed will consist of exposed alveolar bone and bone graft imbedded in coagulum of blood from the socket for both treatments. The test treatment GINTUIT will be inlayed within the defect over the socket graft material, and stabilized with resorbable tacking sutures. An additional single layer of GINTUIT will cover the entire surface of the extraction socket at approx. 2-3 mm beyond the margins of the wound and fixed with non-resorbable sutures. The lower layer of this additional layer should be in contact with the previously applied GINTUIT.

Biological: Gintuit

Bio-Gide

ACTIVE COMPARATOR

Subjects with a posterior tooth (molar or premolar) socket created by atraumatic extraction will be grafted with freeze-dried bone allograft (ie, MinerOss™). The primary wound bed will consist of exposed alveolar bone and bone graft imbedded in coagulum of blood from the socket for both treatments. The control treatment will be a collagen membrane (ie, Bio-Gide, applied per the Package Insert) inlayed within the defect over the socket graft material, and stabilized with resorbable tacking sutures. Crossed suspensory type sutures should also be placed over Bio-Gide, depending on the degree of stabilization needed. In all subjects, care should be taken in suturing to avoid advancement of the buccal gingival flap.

Device: Bio-Gide

Interventions

Gintuit BIOLOGICAL

One time placement of Gintuit over socket graft.

Gintuit

Bio-Gide DEVICE

One time placement of Bio-Gide over socket graft.

Bio-Gide

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subject is at least 18 years of age but no more than 75 years of age.
• Subject has a posterior (molar or premolar) socket created by atraumatic extraction with a post extraction socket of a minimum of 5 mm in both the mesial-distal (M-D) and buccal-lingual (B-L) dimensions that requires bone grafting.
• Subject has sufficient buccal bone plate at the site of the planned tooth extraction (ie, the residual socket should be of a form that would retain bone graft material), as judged by the Principal Investigator.
• Females of childbearing potential must have a documented negative urine pregnancy test. All subjects must agree to use acceptable methods of contraception for the duration of the study.
• Subjects must have read, understood, and signed an institutional review board (IRB)-approved Informed Consent Form (ICF).
• Subjects must be able and willing to comply with protocol requirements.

You may not qualify if:

• Subject with any systemic conditions that could compromise wound healing and preclude periodontal surgery (ie, bleeding disorder, cancer, except localized basal cell or squamous cell cancer of the skin with no metastasis; human immunodeficiency virus; or bone metabolic diseases \[ie, osteoporosis or Paget's disease\]).
• Subject who is currently receiving, anticipates receiving or has received within 30 days prior to Day 0: inhaled or systemic corticosteroids (ie, oral, IV), immunosuppressive agents or radiation therapy, and/or chemotherapy, which could compromise wound healing and preclude periodontal surgery.
• Subject who has had oral/periodontal surgery within 30 days prior to Day 0 or anticipates having oral/periodontal surgery within 30 days after Day 0.
• Subject with acute mucosal infection, including suppuration or induration in the area of intended surgery.
• Subject, who in the opinion of the Principal Investigator, will require a sinus lift procedure to place dental implants in the surgical area.
• Subject without at least 1 tooth adjacent to the area to be treated.
• Subject has a history of alcohol or substance abuse within the previous 12 months of Screening that could interfere with study compliance or protocol requirements.
• Subject who has used any tobacco product within 6 months of Screening.
• Subject with known hypersensitivity to porcine or bovine collagen, gentamicin or surfactants.
• Subject who has received an investigational drug, device, or biological/bioactive treatment within 30 days prior to Day 0 (medical or dental).
• Subject who was previously treated with Gintuit, or any other cell therapy at the target treatment site or immediately adjacent teeth.
• Female subject that is lactating.
• Subject, who in the opinion of the Principal Investigator, for any reason other than those listed above, will not be able to complete the study per protocol.

Sponsors & Collaborators

• Organogenesis: lead

Study Sites (1)

Kevin G. Murphy and Associates, P.A.

Baltimore, Maryland, 21209, United States

Location

Study Officials

• Kevin G. Murphy, DDS, MS

  Kevin G. Murphy Associates, P.A.

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 13, 2013
• First Posted: August 28, 2013
• Study Start: July 1, 2013
• Primary Completion: March 1, 2015
• Study Completion: March 1, 2015
• Last Updated: September 24, 2015

Record last verified: 2015-09

Locations

US (1)